Scientific Sessions 2025  /  Annual Lipid Update 2025  /  What LDL-C (or ApoB) level should we be targeting? And how ASCVD history inform LDL-C targets?
Logo

American Heart Association

  39
  0

Final ID:

What LDL-C (or ApoB) level should we be targeting? And how ASCVD history inform LDL-C targets?

  • Khera, Amit  ( UT Southwestern , Dallas , Texas , United States )
  • Joshi, Parag  ( UT Southwestern Medical Center , Dallas , Texas , United States )
    • Author Disclosures:
    Amit Khera: DO NOT have relevant financial relationships | Parag Joshi: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Consultant:New Amsterdam Pharma:Past (completed) ; Consultant:Kaneka:Past (completed) ; Consultant:Novartis:Past (completed) ; Research Funding (PI or named investigator):Kaneka:Past (completed) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Annual Lipid Update 2025

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Will apoCIII therapies tip the BALANCE towards targeting triglycerides?

Tsimikas Sotirios, Ballantyne Christie

Targeting PCSK9 to lower LDL-C and CVD risk – A growing array of options

Bohula Erin, Odonoghue Michelle

More abstracts from these authors:
Need for Testing Standardization and Improved Treatment of Elevated Lipoprotein(a) at a Large Urban Academic Medical Center

Wong Willis, Kao Cindy Hsin-yi, Schneider Ruth, Navar Ann Marie, Rohatgi Anand, Khera Amit, Joshi Parag

Physician-Level Variation in Lipid Management for Secondary Prevention of Atherosclerotic Cardiovascular Disease: Opportunities for Practice Improvement

Nguyen Danh, Hwang Jimin, Peterson Eric, Rohatgi Anand, Joshi Parag, Khera Amit, Navar Ann Marie

You have to be authorized to contact abstract author. Please, Login
Not Available